MEDICAL CHANNEL ASIA

PUBLIC PORTAL

PUBLIC PORTAL

MEDICALLY REVIEWED

HSA Approves First-In-Class Sacituzumab Govitecan (Trodelvy) for Metastatic Triple Negative Breast Cancer (mTNBC)

breast cancer trodelvy sacituzumab govitecan

Disease burden and treatment landscape
Breast cancer is the leading cause of death among Singaporean women and accounts for over 30% of all cancers diagnosed in women. It is a . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: